Chemical structure of Actinomycin D.
Western blot analysis of extracts from MCF7 cells, untreated (-) or treated with Actinomycin D (1 μM) for the indicated times, using Phospho-Histone H2A.X (Ser139) (20E3) Rabbit mAb #9718 (upper) and Histone H2A.X (D17A3) XP® Rabbit mAb #7631 (lower).
Western blot analysis of extracts from MCF7 cells, untreated (-) or treated with Actinomycin D (1 μM) for the indicated times, using Phospho-p53 (Ser15) Antibody #9284 (upper), p53 (7F5) Rabbit mAb #2527 (middle), and β-Actin (D6A8) Rabbit mAb #8457 (lower).
Actinoymcin D is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 5 mg in 398.28 μl DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 10-1,000 nM for 6-48 hr.
Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 1 week to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|MW (kDa)||1255.4 g/mol|
|Solubility||Soluble in DMSO at 50mg/ml.|
Actinomycin D is an effective anti-tumor agent and the most widely studied member of the actinomycin group of antibiotics (1). The compound, isolated from soil bacteria of the Streptomyces genus, is comprised of two cyclic pentapeptides bound by a phenoxazone group (2,3). Actinomycin D inhibits mRNA transcription in mammalian cells. Actinomycin D intercalates DNA and stabilizes topoisomerase I-DNA covalent complexes, blocking RNA chain elongation by RNA polymerase and consequently inhibiting protein synthesis (1,4,5). This mechanism of action induces p53-mediated cell cycle arrest in numerous cancer cell lines (6,7) and at high concentrations can induce apoptosis (8). Additional research studies show that Akt mediates actinomycin D-induced p53 expression (9).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.